Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 11/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | CCR9 | P51686 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26485807 | 0.86 | MAT2A (0.48) | MAT2APRMT5CYP3A4TRPV1 | |
| SCHEMBL26489377 | 0.84 | MAT2A (0.46) | MAT2APRMT5CYP3A4 | |
| SCHEMBL26485643 | 0.83 | MAT2A (0.43) | MAT2APRMT5SMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL26488687 | 0.82 | MAT2A (0.39) | MAT2APRMT5SMN1; SMN2CYP3A4MAPT | |
| SCHEMBL30420483 | 0.82 | MAT2A (0.39) | MAT2APRMT5SMN1; SMN2CYP3A4MAPT | |
| SCHEMBL26485808 | 0.79 | MAT2A (0.50) | MAT2APRMT5CCR9 | |
| SCHEMBL31026798 | 0.78 | MAT2A (0.37) | MAT2APRMT5CYP3A4CCR9 | |
| SCHEMBL26489468 | 0.78 | MAT2A (0.37) | MAT2APRMT5CYP3A4CCR9 | |
| SCHEMBL26489039 | 0.77 | MAT2A (0.41) | MAT2APRMT5SMN1; SMN2CYP3A4TRPV1 | |
| SCHEMBL30420090 | 0.76 | MAT2A (0.67) | MAT2APRMT5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042890-A1 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2025-02-06 | — | — | US | disclosed |
| CN-118434722-A | Methionine adenosyltransferase 2A (MAT 2A) inhibitors and uses thereof | 英矽智能科技知识产权有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-11999713-B2 | Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2024-06-04 | — | — | US | disclosed |
| US-20240132465-A1 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| WO-2023066283-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999713-B2 | Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof | MAT2A, MAT2B, MAT1A | MAT2A 1/4885PRMT5 48/4885VNN1 2109/4885 |
| US-20250042890-A1 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | MAT2A, MAT2B, MAT1A | MAT2A 1/4885PRMT5 48/4885VNN1 2109/4885 |
| US-20240132465-A1 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | MAT2A, MAT2B, MAT1A | MAT2A 1/4885PRMT5 48/4885VNN1 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.